https://www.aasraw.com/experimental-drug-j147-alzheimers-aging/ Alzheimer's is at the forefront of biomedical research.Researchers are working to uncover Alzheimer's drug(AD drug) candidates: J147, CMS121, CAD31

1. www.aasraw.com
1 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
Alzheimer’s drug(AD drug) candidates:
J147, CMS121, CAD31
Alzheimer’sdrug(ADdrug)candidates:J147,CMS121,CAD31.......................................1
What is Alzheimer’s and Geroprotectors(GNPs).............................................2
Cause of Alzheimer’s disease............................................................................ 3
Alzheimer’s drug(AD drug) candidates: J147, CMS121, CAD31................. 4
– Alzheimer’s drug(AD drug) candidates: J147........................................4
– Alzheimer’s drug(AD drug) candidates:CMS121.................................. 6
– Alzheimer’s drug(AD drug) candidates:CAD31.....................................7
Conclusion.............................................................................................................8

2. www.aasraw.com
2 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
What is Alzheimer’s and Geroprotectors(GNPs)
Alzheimer’s is the most common cause of dementia,is a type of dementia that
causes problems with memory, thinking and behavior. Symptoms usually
develop slowly and get worse over time, becoming severe enough to interfere
with daily tasks.Alzheimer’s disease accounts for 60 percent to 80 percent of
dementia cases. And old age is the greatest risk factor for many diseases,
including Alzheimer’s disease (AD) and cancer.
Geroprotectors, it is a senotherapeutic that aims to affect the root cause of
aging and age-related diseases, and thus prolong the life span of animals.
New Salk research has now identified a unique subclass of these compounds,
dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow
the aging process in mice.

3. www.aasraw.com
3 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
Cause of Alzheimer’s disease
Researchers believe there is not a single cause of Alzheimer’s disease. How
do you get Alzheimer’s disease? The disease likely develops from multiple
factors, such as genetics, lifestyle and environment. Scientists have identified
factors that increase the risk of Alzheimer’s. While some risk factors — age,
family history and heredity — can’t be changed, emerging evidence suggests
there may be other factors we can influence.
-Age
The greatest known risk factor for Alzheimer’s is increasing age, but
Alzheimer’s is not a normal part of aging. While age increases risk, it is not a
direct cause of Alzheimer’s.
Most individuals with the disease are 65 and older. After age 65, the risk of
Alzheimer’s doubles every five years. After age 85, the risk reaches nearly
one-third.
-Family history
Another strong risk factor is family history. Those who have a parent, brother
or sister with Alzheimer’s are more likely to develop the disease. The risk
increases if more than one family member has the illness.
-Genetics (heredity)
Scientists know genes are involved in Alzheimer’s. Two categories of genes
influence whether a person develops a disease: risk genes and deterministic
genes.
-Head injury
There is a link between head injury and future risk of dementia. Protect your
brain by buckling your seat belt, wearing your helmet when participating in
sports, and “fall-proofing” your home.
-Heart-head connection
Some of the strongest evidence links brain health to heart health. This
connection makes sense, because the brain is nourished by one of the body’s

4. www.aasraw.com
4 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
richest networks of blood vessels, and the heart is responsible for pumping
blood through these blood vessels to the brain.
Alzheimer’s drug(AD drug) candidates: J147,
CMS121, CAD31
Today, Alzheimer’s is at the forefront of biomedical research. Researchers are
working to uncover as many aspects of Alzheimer’s disease and other
dementias as possible. Some of the most remarkable progress has shed light
on how Alzheimer’s affects the brain. The hope is this better understanding will
lead to new treatments. Many potential approaches are currently under
investigation worldwide.
Salk’s Cellular Neurobiology Laboratory started with two chemicals found in
plants that have demonstrated medicinal properties: fisetin, a natural product
derived from fruits and vegetables, and curcumin, from the curry spice turmeric.
From these, the team synthesized three AD drug candidates based upon their
ability to protect neurons from multiple toxicities associated with the aging
brain. The lab showed that these three synthetic candidates (known as
CMS121, CAD31 and J147), as well as fisetin and curcumin, reduced the
molecular markers of aging, as well as dementia, and extended the median
lifespan of mice or flies.
Importantly, the group demonstrated that the molecular pathways engaged by
these AD drug candidates are the same as two other well-researched synthetic
compounds that are known to extend the lifespan of many animals. For this
reason, and based on the results of their previous studies, the team says
fisetin, curcumin and the three AD drug candidates all meet the definition of
being geroneuroprotectors.
Other studies in the lab are determining whether these compounds have
effects on organs outside of the brain. “If these drugs have benefits for other
body systems, such as maintaining kidney function and overall muscle health,
they could be used in additional ways to treat or prevent the diseases of
aging,” Schubert says.
– Alzheimer’s drug(AD drug) candidates: J147
Curcumin, the main ingredient of the Indian curry spice turmeric, is a
multitarget compound that reduces inflammation, ROS production, amyloid

5. www.aasraw.com
5 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
toxicity, and excitotoxicity, and is very effective in rodent models of AD.
However, curcumin has very low neurotrophic activity, poor bioavailability, and
poor brain penetrance. To improve the neurotrophic activity and metabolic
stability of curcumin, we used SAR driven iterative chemistry to improve the
pharmacological properties while at the same time increasing its potency and
aspects of its biological activities. Initially the highly labile diketo system of
curcumin was modified to a pyrazole to make CNB-001, with improved stability
and neuroprotective activity over curcumin. Systemic exploration of groups on
three phenyl rings of CNB-001 revealed that the hydroxyl groups are not
necessary for activity in the seven screening assays. The addition of two
methyl groups to the pyrazole attached phenyl ring led to CNB-023 with
improved potency over CNB-001. However, CNB-023 is highly lipophilic
(cLogP = 7.66), and compounds with high lipophilicity have multiple liabilities.
To reduce the lipophilicity and identify the minimal structural requirements for
activity, one of the two cinnamyl groups was removed and further optimization
led to an extremely potent small molecule J147. J147 is 5–10 times more
potent in all of the screening assays as CNB-001, while curcumin has little or
no activity in any assay. J147 is not only highly potent but also it has good
physicochemical properties (MW = 350, cLogP = 4.5, tPSA = 42). J147
(1146963-51-0) has been studied extensively in normal aged and AD models
where it has outstanding therapeutic efficacy.

6. www.aasraw.com
6 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
Somebody concern that does J147 can be degraded to aromatic
amines/hydrazines that are potentially carcinogenic. To explore this possibility,
the metabolic stability of J147 was studied in microsomes, in mouse plasma,
and in vivo. It was shown that J147 (1146963-51-0) is not degraded to
aromatic amines or hydrazines, that the scaffold is exceptionally stable, and
that it is modified to two or three oxidative metabolites in human, mouse, rat,
monkey, and dog liver microsomes. To examine the safety of these
metabolites, we have synthesized all three human liver microsomal
metabolites and assayed them for biological activity in the neuroprotection
assays. None of these metabolites are toxic, and many of the metabolites have
biological activities similar to those of J147.
– Alzheimer’s drug(AD drug) candidates:CMS121
CMS121 is the derivative of fisetin. Over the past few years, we have shown
that the flavonoid fisetin is an orally active, neuroprotective, and
cognition-enhancing molecule in several animal models of CNS disorders.
Fisetin has direct antioxidant activity and can maintain the intracellular levels of
GSH under stress. In addition, fisetin has both neurotrophic and
anti-inflammatory activity. This wide range of actions suggests that fisetin has
the ability to reduce the loss of neurological function associated with multiple
disorders. However, its relatively high EC50 in cell based assays (2–5 μM), low
lipophilicity (cLogP 1.24), high tPSA (107), and poor bioavailability have limited
fisetin for further development as a drug candidate.

7. www.aasraw.com
7 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
The challenge was to improve the potency of fisetin in multiple neuroprotective
pathways while at the same time altering its physicochemical properties to be
more consistent with those of successful CNS drugs (molecular weight ≤ 400,
cLogP ≤ 5, tPSA ≤ 90, HBD ≤ 3, HBA ≤ 7).Two different approaches were used
to improve fisetin. In the first, the different hydroxyl groups were modified in a
systematic manner to eliminate possible sulfate/glucuronidate metabolites. In
the second approach, the flavone scaffold was changed to a quinoline, while at
the same time maintaining key structural elements of fisetin.Utilizing our
multitarget drug discovery approach, we have generated a number of
derivatives with greatly enhanced activities in the neuroprotective oxytosis and
in vitro ischemia assays. Three additional activities of fisetin were retained in
the derivatives, including the maintenance of GSH, inhibition of bacterial
lipopolysaccharide (LPS) induced microglial activation, and PC12 cell
differentiation, a measure of neurotrophic activity. Flavone derivative CMS-140
and quinolone derivative CMS-121 are 600 and 400 times more potent,
respectively, than fisetin in the ischemia assay (Figure ​ . Thus, it is possible
to maintain the multitarget qualities of a polyphenol while improving both the
physiochemical and pharmacological properties of the compound.
– Alzheimer’s drug(AD drug) candidates:CAD31
All of the multiple physiological effects of CAD31 were favorable in the context
of preventing some of the toxic events in old age-associated
neurodegenerative diseases.
CAD31 is an Alzheimer’s disease (AD) drug candidate that was selected on
the basis of its ability to stimulate the replication of human embryonic stem
cell-derived neural precursor cells as well as in APPswe/PS1ΔE9 AD mice. To
move CAD-31 toward the clinic, experiments were undertaken to determine its
neuroprotective and pharmacological properties, as well as to assay its
therapeutic efficacy in a rigorous mouse model of AD.
CAD31 has potent neuroprotective properties in six distinct nerve cell assays
that mimic toxicities observed in the old brain. Pharmacological and
preliminary toxicological studies show that CAD31 is brain-penetrant and likely
safe. When fed to old, symptomatic APPswe/PS1ΔE9 AD mice starting at 10
months of age for 3 additional months in a therapeutic model of the disease,
there was a reduction in the memory deficit and brain inflammation, as well as
an increase in the expression of synaptic proteins. Small-molecule metabolic
data from the brain and plasma showed that the major effect of CAD-31 is
centered on fatty acid metabolism and inflammation. Pathway analysis of gene

8. www.aasraw.com
8 AASraw Biochemical Technology Co.,Ltd
aas14@aasraw.com
expression data showed that CAD-31 had major effects on synapse formation
and AD energy metabolic pathways.
Conclusion
Research group is now focusing on getting two GNPs into human clinical trials.
The fisetin derivative, CMS121, is currently in the animal toxicology studies
required for FDA approval to start clinical trials. The curcumin derivative, J147,
is under FDA review for allowance to start clinical trials for AD early next year.
The group plans to incorporate biochemical markers for aging into the clinical
trials to assay for potential geroprotective effects.The investigators say that the
discovery of these AD drug candidates validates the drug discovery model
they have developed as a plausible method for identifying additional GNP
compounds that will help promote healthy aging. This could greatly accelerate
the pipeline for drugs to treat the diseases of aging for which there are
currently no cures.